Leukaemia: Drugs

Health written question – answered on 17th July 2007.

Alert me about debates like this

Photo of James Gray James Gray Conservative, North Wiltshire

To ask the Secretary of State for Health pursuant to the answer of 10 July 2007, Official Report, column 1450W, on leukaemia: drugs, what the reasons were for deciding not to refer dasatnib to the National Institute for Health and Clinical Excellence; and in what circumstances the drug would be considered for referral in the future.

Photo of Dawn Primarolo Dawn Primarolo The Parliamentary Under-Secretary of State for Health

The Department has not received a proposal from the National Institute for Health and Clinical Excellence (NICE) for an appraisal of dasatinib for chronic myeloid leukaemia. However, I understand that NICE is currently considering a proposal for an appraisal of this treatment against its published criteria for the selection of topics.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.


No annotations

Sign in or join to post a public annotation.